Global High-Priority Regulatory Events — June 04, 2026

04-06-2026

04-06-2026

Rolex Rings Limited has announced a buyback of up to 10,000,000 equity shares at ₹180 per share, for a total consideration not exceeding ₹1,800.00 million, via the tender offer route. The buyback was approved by the board on April 23, 2026, and by shareholders on May 31, 2026. The public announcement was published on June 4, 2026, in Financial Express (English), Jansatta (Hindi), and Financial Express (Gujarati).

• · The buyback is being conducted on a proportionate basis through the tender offer route.
• · The buyback was approved by the board on April 23, 2026, and by shareholders on May 31, 2026.
• · The public announcement was published on June 4, 2026, in three newspapers: Financial Express (English), Jansatta (Hindi), and Financial Express (Gujarati).

04-06-2026

IndiGo reported a Q4 FY26 net loss of ₹25,400 Cr (vs net profit of ₹30,700 Cr in Q4 FY25), and a full-year FY26 net loss of ₹23,900 Cr. The losses were driven by a sharp 11% rupee depreciation against the USD causing large FX losses, the impact of the December 2025 operational disruption, and geopolitical tensions in the Middle East that disrupted international routes. However, excluding FX and exceptional items, the airline delivered an underlying net profit of ₹19,200 Cr in Q4 and ₹75,000 Cr for the full year, while serving a record 123 million passengers.

• · The December disruption had an estimated total impact of ~₹21,800 Cr (₹5,800 Cr exceptional + ₹15,000-16,000 Cr on capacity/revenue).
• · Approximately 18% of total capacity and 160 daily flights to/from Middle East and Europe were disrupted by geopolitical tensions.
• · Capacity growth in Q4 was only 3% due to Middle East disruptions, well below the planned ~10% trajectory seen in Jan-Feb.
• · Fuel CASK declined 5% YoY in Q4 due to benchmark price decline and a natural lag in fuel price pass-through.
• · CASK ex fuel ex forex rose 7% YoY in Q4 driven by rupee depreciation (5% avg), lower aircraft utilization, and annual contractual cost increases.
• · More than 50% of IndiGo's costs are dollar-denominated, amplifying FX sensitivity.
• · Fleet grew to 441 aircraft at March 31, 2026 (from 406 a year earlier), with 72 gross additions and 65 redeliveries.
• · Pratt & Whitney groundings (AOG) are in the 40s, expected to trend down to the 30s by end of the next financial year.
• · Willie Walsh has been appointed as CEO (joining early August 2026), and Aloke Singh as Chief Strategy Officer.
• · The Q4 FY25 comparison base was unusually high due to the Maha-Kumbh religious festival.
• · Government intervention helped soften the impact of global jet fuel price increases on domestic operations.

04-06-2026

Future Consumer Ltd disclosed that the NCLT (Mumbai) hearing in the insolvency case filed by State Bank of India (SBI) has been adjourned to June 8, 2026, with the company directed to file written submissions. The company argued that an ongoing arbitration with a JV partner could yield a positive order, and also raised a preliminary issue regarding its NBFC classification, which remains unresolved.

• · The NCLT case was filed by SBI against Future Consumer Ltd, with the debt authenticated via sanction letters, recall notice, NESL report, and a revival letter.
• · The company's counsel submitted that an ongoing arbitration with a JV partner could result in a positive order.
• · A preliminary issue regarding whether the company qualifies as an NBFC due to the size of its investment is yet to be decided by the NCLT bench.
• · The matter has been adjourned to June 8, 2026, to be heard alongside the Resurgent matter.

04-06-2026

WISeKey and its subsidiary WISeSat.Space Corp. announced the confidential submission of an amended draft registration statement on Form F-4 with the SEC on May 29, 2026, in connection with their proposed business combination with Columbus Acquisition Corp (CAC), a SPAC. The combined company is expected to trade on Nasdaq under the ticker symbol "WSAT." However, the transaction remains subject to several closing conditions, including SEC effectiveness, CAC shareholder approval, and Nasdaq listing approval, and there is no guarantee that the business combination will be completed in a timely manner or at all.

• · The amended draft registration statement was confidentially submitted to the SEC on May 29, 2026.
• · The Business Combination Agreement was originally dated November 9, 2025.
• · WISeSat is a British Virgin Islands business company operating through its wholly owned subsidiary WISeSat.Space AG.
• · CAC is led by Fen 'Eric' Zhang (Chairman and CEO) and Jie 'Janet' Hu (CFO).
• · Maxim Group LLC is acting as exclusive financial advisor to WISeKey; Ellenoff Grossman & Schole LLP is legal advisor to WISeSat and Pubco; Loeb & Loeb LLP is legal advisor to CAC.
• · WISeKey has deployed over 1.6 billion microchips across various IoT sectors.

04-06-2026

X-Energy, Inc. reported a net loss of $166.2M for Q1 2026, a significant increase from a $10.2M loss in Q1 2025, driven by a $108.9M mark-to-market loss on warrant liabilities. Total revenues and grant income more than doubled to $43.4M from $20.8M, primarily due to a 133.5% surge in services revenue to $39.9M. However, operating expenses also more than doubled to $109.5M, and cash and cash equivalents fell sharply from $458.9M to $224.1M.

• · Accounts receivable from DOE decreased from $23.6M at Dec 31, 2025 to $20.0M at Mar 31, 2026.
• · Unbilled receivables and contract assets from DOE increased from $39.6M to $51.1M.
• · Capital expenditures increased significantly to $43.0M in Q1 2026 from $11.2M in Q1 2025, partially offset by $28.8M in government grant reimbursements.
• · The company issued 19,576,222 Series C-1 Preferred Units upon conversion of the 2024 Warrant, increasing mezzanine equity by $365.2M.
• · Unit-based compensation expense rose to $4.3M in Q1 2026 from $65K in Q1 2025.
• · Total assets remained relatively flat at $1.20B vs $1.21B at year-end 2025.
• · The company's accumulated deficit grew to $1.40B from $1.24B at Dec 31, 2025.

04-06-2026

NextTrip, Inc. (NTRP) borrowed $200,000 on May 29, 2026 from The Donald P. Monaco Insurance Trust, a related party (director Donald P. Monaco is trustee), as part of a series of short-term unsecured loans. The total principal balance of these Monaco Loans is now $500,000, accruing interest at 7.5% simple interest per annum, with a maturity date of June 30, 2026. The loans were approved by the Board of Directors and Audit Committee, but the short-term nature and reliance on insider funding may signal liquidity constraints.

• · The Monaco Loans commenced on March 25, 2026, and the $200,000 borrowed on May 29 is the latest in that series.
• · The loans are unsecured and mature on June 30, 2026, indicating very short-term financing.
• · The loans were approved by both the Board of Directors and the Audit Committee, suggesting governance oversight of the related-party transaction.

04-06-2026

Watu Metals Acquisition Corp filed an S-1 registration statement for an IPO of 10,000,000 units at $10.00 per unit, with an over-allotment option of up to 1,500,000 units. The sponsor will purchase 230,000 private units (up to 246,500 if over-allotment is exercised) for $2,300,000. Net proceeds of $100,500,000 (or $115,575,000 if over-allotment exercised) will be held in trust, representing $10.05 per public unit. The company has 12 months from the effective date to complete a business combination or will redeem public shares.

• · The sponsor purchased initial shares at approximately $0.009 per share.
• · Each public right entitles the holder to receive one-eighth (1/8) of one ordinary share upon consummation of a business combination.
• · Rights will expire worthless if no business combination is completed within 12 months.
• · Initial shares are subject to a lock-up: 50% until six months after business combination or when share price reaches $11.50 for 20 trading days within 30, and the remaining 50% for six months after business combination.
• · Private units are locked up for 30 days following business combination.
• · Representative shares are locked up for 180 days from commencement of sales per FINRA Rule 5110(e)(1).
• · The company must complete a business combination within 12 months from the effective date of the registration statement or redeem public shares.

04-06-2026

CrowdStrike reported a net income of $27.8M for Q1 FY26, a significant turnaround from a net loss of $104.3M in Q1 FY25. Total revenue grew 25.6% YoY to $1.39B, driven by subscription revenue growth of 25.7%. However, the company generated negative operating cash flow from changes in deferred revenue, which declined $36.7M, and cash and cash equivalents fell 12.9% from January 2026 to $4.55B, partly due to $881.4M in acquisition spending and $175.6M in share repurchases.

• · Subscription gross margin improved to 78.2% in Q1 FY26 from 77.0% in Q1 FY25.
• · Professional services gross margin declined to 16.9% in Q1 FY26 from 11.7% in Q1 FY25.
• · Stock-based compensation expense was $297.7M in Q1 FY26, up from $247.7M in Q1 FY25.
• · The company repurchased 480,000 shares for $175.6M during Q1 FY26.
• · Goodwill increased 66.3% to $2.27B due to acquisitions.
• · Deferred revenue (current) declined 1.5% sequentially to $3.37B.
• · Cash used in investing activities was $994.1M, primarily for acquisitions.
• · Net cash provided by operating activities increased 53.8% YoY to $590.9M.

04-06-2026

America Great Health reported a net loss of $85,363 for the three months ended September 30, 2025, a significant improvement from a net loss of $146,967 in the same period last year. Revenue increased 33.8% to $187,559, driven by strong growth in the United States segment. However, the company remains deeply insolvent with a shareholders' deficit of $5,829,109 and total liabilities of $6,070,405, while cash declined 36.3% to $28,079.

• · Revenue from the United States segment surged 144.7% to $60,425 (32% of total) from $24,692 (17% of total) in Q3 FY24.
• · Asia segment revenue grew 7.2% to $127,134 from $118,647, but its share of total revenue fell from 83% to 68%.
• · Cost of goods sold increased 560.6% to $74,880 from $11,335, causing gross margin to contract from 91.9% to 60.1%.
• · Selling, general and administrative expenses decreased 41.9% to $116,063 from $199,650, primarily due to a 48.5% drop in general and administrative expense.
• · Interest expense rose 7.7% to $81,982 from $76,127, contributing to total other expenses of $81,979.
• · Net cash used in operating activities improved to a positive $44,466 from negative $95,578 in the prior year period.
• · Net cash used in financing activities was $60,524, compared to $88,371 provided in Q3 FY24.
• · Total current liabilities of $3,779,008 exceed total current assets of $185,048 by a ratio of 20.4:1, indicating severe liquidity risk.
• · Accumulated deficit deepened to $10,866,708 from $10,781,345 at June 30, 2025.
• · The company has no accounts receivable and a $9,000 inventory valuation reserve.

04-06-2026

AVITA Medical, Inc. held its 2026 Annual Meeting on June 3, 2026, where stockholders approved all 15 proposals, including the election of all seven director nominees, an increase in the non-executive director cash fee pool from $750,000 to $900,000 per annum, and the issuance of equity awards to directors and officers. However, several proposals received notable opposition, with votes against ranging from approximately 1.8 million to 2.7 million shares, and broker non-votes of 3.89 million shares on most items, indicating mixed shareholder sentiment on certain governance and compensation matters.

• · All seven director nominees were elected with votes for ranging from 10,700,424 to 11,176,792, and votes withheld from 525,113 to 1,001,481.
• · Ratification of Grant Thornton LLP as independent auditor passed with 14,962,654 votes for, 255,151 against, and 374,642 abstentions.
• · Proposal to increase director fee pool to $900,000 passed with 8,582,602 for, 2,710,656 against, and 408,647 abstentions (plus 3,890,542 broker non-votes).
• · Annual equity grants to each non-executive director (22,214 RSUs and 16,133 options) passed with votes for ranging from 8,722,810 to 8,869,562, and votes against from 2,411,009 to 2,544,450.
• · Initial grant to Dr. Michael Tarnoff (26,250 RSUs and 19,063 options) passed with 8,791,498 for, 2,433,367 against, and 477,040 abstentions.
• · Initial grant to Joseph Woody (40,547 RSUs and 29,446 options) passed with 8,863,312 for, 2,395,376 against, and 443,217 abstentions.
• · Advisory vote on executive compensation (Say-on-Pay) passed with 8,918,272 for, 2,202,213 against, and 581,420 abstentions.
• · Advisory vote on frequency of Say-on-Pay favored 1 year with 9,545,151 votes, versus 924,743 for 2 years, 650,252 for 3 years, and 581,759 abstentions.
• · Issuance of warrants to Perceptive (up to 650,000 shares, 10-year term) passed with 9,322,532 for, 1,769,627 against, and 609,746 abstentions.
• · Approval to issue additional 10% equity securities under ASX Rule 7.1A passed with 8,947,195 for, 2,223,106 against, and 531,604 abstentions.

04-06-2026

Spring Valley Acquisition Corp. III (SVAC) filed a 425 communication regarding its proposed business combination with General Fusion Inc., a fusion energy developer. The transaction implies a pro-forma equity value of approximately $1 billion, including a $107.7 million PIPE and about $230 million from SVAC's trust capital. General Fusion, which has raised over $400 million to date, plans to use proceeds to advance its LM26 demonstration program and targets a first commercial plant by the mid-2030s, but has not yet built a commercial reactor producing net energy.

• · General Fusion was founded in 2002 and is one of the oldest privately funded fusion ventures.
• · The company's MTF approach uses a liquid-lithium liner to compress magnetized plasma, avoiding superconducting magnets and high-powered lasers.
• · LM26 milestones: heat plasma to 1 keV (10 million °C), then 10 keV (100 million °C), and ultimately reach the Lawson criterion for net fusion energy.
• · Spring Valley's earlier SPAC vehicles took NuScale Power and Eagle Nuclear Energy public, and brought Renewable Energy Group public at $10/share (later sold to Chevron for $61.50/share in ~$3B sale).
• · NuScale Power has $1B liquidity and a 6 GW deployment program with ENTRA1 Energy and TVA; its SMR design is NRC-approved.
• · Oklo's Aurora powerhouse received NRC approval for Principal Design Criteria, with commercial deployment at Idaho National Lab targeted for late 2027.
• · Centrus Energy raised full-year revenue guidance and has a $2.3B LEU backlog plus a $900M HALEU award.
• · NANO Nuclear submitted a Construction Permit Application to the NRC for its KRONOS MMR prototype at University of Illinois.
• · The combined company is expected to trade on Nasdaq under ticker 'GFUZ' after closing targeted for mid-2026.
• · General Fusion's leadership will participate in Stifel Boston Conference (June 2-3), ROTH London Conference (June 16-18), and FusionX:Americas (June 9-11).

04-06-2026

ROKIT America, Inc. filed Amendment No. 2 to its S-1 registration statement for an initial public offering of 2,631,579 shares of common stock, with an estimated price range of $8.50 to $10.50 per share (midpoint $9.50). The company, an emerging growth and smaller reporting company, plans to list on Nasdaq under the symbol "RKAM" and expects gross proceeds of approximately $25.0 million (or $28.75 million with full over-allotment). The offering is underwritten by Maxim Group LLC, with a 6.5% underwriting discount and a 45-day over-allotment option for up to 394,737 additional shares. The company focuses on dietary supplements (NMN-based Reverse Aging Products) and an AI-driven Organ Regeneration Platform licensed from its parent, ROKIT Healthcare, but faces risks including no existing public market, reliance on a single parent company, and a highly competitive dietary supplement market with low barriers to entry.

• · The company was founded in 2019 and has focused on NMN-based dietary supplements.
• · The company's parent, ROKIT Healthcare, is a publicly traded company in South Korea and will remain a major stockholder after the offering.
• · The company has applied to list on Nasdaq under the symbol 'RKAM'.
• · The offering is contingent upon Nasdaq listing approval.
• · The company has elected to comply with reduced reporting requirements as an emerging growth company and smaller reporting company.
• · The dietary supplement market is highly competitive with low barriers to entry.
• · The company's ORP technology is licensed from ROKIT Healthcare under an Intellectual Property License Agreement dated August 27, 2025.
• · The company has a Support Agreement with ROKIT Healthcare for financial, legal, HR, sales, and marketing services.
• · The company has an Advisory Service Agreement with CKIUFC (controlled by CFO Ha Young Kim) for operational advisory and CFO services.
• · The underwriters will receive warrants to purchase 5% of the shares sold at 125% of the IPO price (not registered under this S-1).

04-06-2026

Gentherm announced its acquisition of Modine's Performance Technologies business via a Reverse Morris Trust, creating a combined company with $2.6B revenue and $320M EBITDA on day one. The deal is expected to close in early Q4 2026. While the core automotive business is expected to grow mid-single digits, the company faces near-term integration risks and the Modine business is coming off a trough in commercial vehicle and off-highway markets.

• · Gentherm expects to double its Medical business to $100M by 2030.
• · The company is consolidating footprint in every region, to be completed by end of 2027.
• · Modine's Performance Technologies business is only 20% light vehicle; other markets include construction, agriculture, mining, commercial vehicle, and power generation.
• · Post-transaction leverage is expected to be just under 1 turn.
• · The transaction is structured as a Reverse Morris Trust with an equity component and distribution.
• · Gentherm realigned organization from regional to functional structure, removing layers of management at director level and above.

04-06-2026

Greenwich LifeSciences reported a net loss of $5.66M for Q1 2026, more than doubling from a $2.74M loss in Q1 2025, driven by a 129% surge in R&D expenses to $5.21M. The company raised $9.03M net through its ATM program, boosting cash to $10.51M from $6.18M at year-end 2025, but operating cash burn also widened to $4.70M from $1.83M. Stockholders' equity improved to $5.27M from $0.35M, though the accumulated deficit grew to $92.79M.

• · Revenue remained zero for both Q1 2026 and Q1 2025.
• · General and administrative expenses increased only 4.1% YoY to $0.52M.
• · Stock-based compensation was unchanged at $1.54M in both periods.
• · Accounts payable decreased 7.5% from $4.87M to $4.51M.
• · Unreimbursed expenses dropped 81.1% from $0.28M to $52,382.
• · Weighted average diluted shares outstanding rose 10.6% to 14.57M.
• · Net loss per share widened from $(0.21) to $(0.39).

04-06-2026

Smith-Midland Corporation received a notice from Nasdaq on May 29, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, violating Nasdaq Listing Rule 5250(c)(1). The notice has no immediate effect on the listing of its common stock on the Nasdaq Capital Market, and the company is working to file the Form 10-Q as promptly as possible. If unable to file by July 28, 2026, the company intends to submit a plan to regain compliance.

• · The company has until July 28, 2026, to file the Form 10-Q or submit a compliance plan to Nasdaq.
• · A press release regarding the late filing was issued on June 3, 2026, and attached as Exhibit 99.1 to the 8-K.

04-06-2026

Atkore Inc. entered into a settlement agreement on June 3, 2026, with the End User Plaintiffs in the In re PVC Pipe Antitrust Litigation, agreeing to pay $50 million to resolve all claims. The settlement is subject to court approval and is expected to be funded from available cash, with no material adverse effect on liquidity or leverage metrics. The company does not admit fault and believes the settlement reduces legal uncertainty, but there is no assurance of final court approval.

• · The settlement will be reflected as a non-operating expense in the quarter ending June 26, 2026.
• · The settlement payment is due on or about 21 days after preliminary court approval.
• · The settlement covers all claims including potential parens patriae claims.
• · The company previously entered into settlement agreements with two of the three putative classes on April 28, 2026.
• · If the settlement is not approved, the company plans to vigorously defend itself.

04-06-2026

Activate Energy Acquisition Corp. appointed David Whitby as a director on May 20, 2026. Mr. Whitby is a retired oil and gas executive who formerly served as Managing Director of Nido Petroleum Ltd., growing it from a market capitalization of A$1 million to A$600 million. The appointment appears to be a standard board addition with no disclosed arrangements, family relationships, or material interests requiring disclosure.

• · Mr. Whitby holds a bachelor of engineering degree from the Royal Military College of Canada
• · There are no family relationships between Mr. Whitby and any other director or executive officer
• · The company is incorporated in the Cayman Islands and files under SEC file number 001-42992
• · The company qualifies as an emerging growth company and has elected not to use the extended transition period for complying with new or revised accounting standards

04-06-2026

Marsh & McLennan Companies, Inc. entered into a $4.25 billion amended and restated five-year credit agreement dated June 2, 2026, replacing its prior $3.5 billion credit agreement from October 2023. The facility is available to the company, Calm Treasury Holdings Limited, MMC Securities LLC, and designated subsidiaries, with Citibank as administrative agent and a syndicate of major banks as joint lead arrangers. The agreement includes customary representations, covenants, events of default, and a guaranty from the company, reflecting an increase in total commitments of $750 million (21.4%) from the prior facility.

• · The agreement is dated June 2, 2026, and was filed as an 8-K on June 4, 2026.
• · Borrowers include the company, Calm Treasury Holdings Limited (formerly MMC Treasury Holdings (UK) Limited), MMC Securities LLC, and any designated subsidiaries.
• · The facility is a five-year revolving credit agreement with a termination date extending the maturity from the prior agreement.
• · The agreement includes a guaranty from Marsh & McLennan Companies, Inc. for obligations of its subsidiaries.
• · The syndication agents include Bank of America, Deutsche Bank, HSBC, JPMorgan Chase, and Wells Fargo.
• · Documentation agents include Barclays, Morgan Stanley, MUFG, PNC, Toronto-Dominion, Bank of Nova Scotia, and Royal Bank of Canada.
• · The agreement contains standard financial covenants, negative pledge, and events of default provisions.
• · The facility can be used for general corporate purposes and includes provisions for letters of credit.

04-06-2026

Parabilis Medicines, Inc. filed an S-1/A registration statement for an IPO of 25,000,000 shares of common stock at an assumed price of $18.00 per share, with an overallotment option for underwriters to purchase up to 3,750,000 additional shares. The company expects net proceeds of approximately $413.6 million from the offering (or $476.4 million if the overallotment is exercised in full), plus an additional $75.0 million from a concurrent private placement with Regeneron. Proceeds will fund clinical development of zolucatetide in desmoid tumors and other indications, pipeline programs, and the Helicon platform. However, the company is not yet profitable, with net losses increasing from $117.9 million in 2024 to $145.9 million in 2025, and a net loss of $45.3 million in Q1 2026 compared to $38.3 million in Q1 2025, reflecting rising R&D and G&A expenses.

• · The company has an accumulated deficit of $586.8 million as of March 31, 2026.
• · Pro forma net loss per share (basic and diluted) for the year ended December 31, 2025 was $(1.81), and for Q1 2026 was $(0.56).
• · Interest income decreased 47.2% from $6.4M in 2024 to $3.4M in 2025, but increased 93.2% from $1.3M in Q1 2025 to $2.4M in Q1 2026.
• · The company's working capital (pro forma as adjusted) is estimated at $776.3 million after the IPO and private placement.
• · The concurrent private placement with Regeneron is at 90% of the IPO price, representing a discount to public investors.
• · The company effected a 1-for-1.5389 reverse stock split on June 3, 2026.
• · The proposed Nasdaq trading symbol is 'PBLS'.

04-06-2026

Somnigroup International Inc. announced that the required 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed merger with Leggett & Platt expired on June 3, 2026, clearing one key regulatory hurdle. The transaction, valued at an undisclosed amount, is expected to close by year-end 2026, but remains subject to several conditions including shareholder approval of Leggett & Platt, additional regulatory clearances in Canada, the EU, the UK, South Korea, and Austria, and the effectiveness of a Form S-4 registration statement. No financial figures or performance metrics were disclosed in this filing.

• · The HSR Act waiting period expired on June 3, 2026, at 11:59 p.m. Eastern Time.
• · Remaining conditions include shareholder approval of Leggett & Platt, clearances under competition laws in Canada, the European Union, the United Kingdom, and the Republic of Korea, and foreign investment approval in Austria.
• · A registration statement on Form S-4 must be filed with the SEC and become effective, with no stop order issued.
• · The merger agreement was originally entered into on April 13, 2026.
• · The transaction is subject to the absence of any material adverse effect on either company since the date of the merger agreement.

04-06-2026

04-06-2026

Leggett & Platt, Incorporated announced that the required 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on June 3, 2026, for its pending merger with Somnigroup International Inc. The transaction, which was previously disclosed on April 13, 2026, is expected to close by year-end 2026, subject to shareholder approval, certain foreign competition and investment clearances, and other customary conditions. No financial figures or period-over-period comparisons are provided in this filing.

• · The Merger Agreement was entered into on April 13, 2026.
• · The HSR Act waiting period expired at 11:59 p.m. Eastern Time on June 3, 2026.
• · Remaining conditions include shareholder approval, clearances under competition laws in Canada, the European Union, the United Kingdom, and the Republic of Korea, and foreign investment approval in Austria.
• · A registration statement on Form S-4 must be filed by Parent and become effective, with no stop order pending.
• · The transaction is subject to the absence of any material adverse effect on either party since the Merger Agreement date.

04-06-2026

Avery Dennison announced the appointment of Danny Allouche as President of its Materials Group. Allouche, previously SVP and Chief Strategy and Corporate Development Officer (and interim CFO in late 2024), brings 16 years of internal experience across strategy, M&A, and treasury. The appointment reflects an internal succession but does not disclose separate financial metrics for the Materials Group vs the broader company.

• · Danny Allouche served as interim CFO for a brief period beginning in late 2024.
• · Allouche holds an MBA from UCLA Anderson School of Management and a bachelor’s in economics from Northwestern University.
• · Avery Dennison employs approximately 35,000 employees in more than 50 countries.
• · Reported sales in 2025 were $8.9B.

04-06-2026

Trulieve Cannabis Corp. completed a deconsolidation transaction on June 3, 2026, spinning off its mixed-use cannabis business (Harvest Enterprises, LLC) to segregate it from its medical cannabis business, aiming to list its subordinate voting shares on the NYSE. The pro forma impact shows a significant reduction in total assets from $2.78B to $2.10B, and a dramatic swing in net income attributable to common shareholders from a reported net income of $2.4M for Q1 2026 to a pro forma net income of $6.0M, but for the full year 2025, the pro forma net loss widened from $116.4M to $802.6M largely due to a one-time $688.7M pre-tax loss on deconsolidation. The retained investment in Harvest is valued at $188.5M under the equity method.

• · Pro forma gross profit was $137.9M for Q1 2026 compared to $170.1M as reported, and $582.1M for FY 2025 compared to $711.2M as reported.
• · Pro forma income from operations was $30.2M for Q1 2026, down from $35.7M as reported.
• · The retained investment in Harvest is classified as equity method investment, not consolidated, and the Non-Voting Units cannot be converted into Common Units until NYSE permits listing of companies that consolidate financials of cannabis businesses with non-medical US operations (Stock Exchange Permissibility Date).
• · Pro forma cash and cash equivalents decreased from $352.9M to $317.6M post-deconsolidation, reflecting the removal of $50.1M in Harvest cash plus $14.8M received in consideration less $3.0M in transaction costs.
• · Pro forma total liabilities decreased by $372.8M, from $1.633B to $1.260B, reflecting removal of Harvest's debt and deferred tax liabilities.
• · The net loss from discontinued operations was eliminated in the pro forma statements, as Harvest is no longer consolidated.

04-06-2026

Regency Fincorp Limited announced the issuance of 50,000 units of secured, rated, listed, non-convertible debentures (NCDs) worth ₹50 Crore, including a base issue of ₹25 Crore and a green shoe option of ₹25 Crore. The NCDs carry a coupon of 13% per annum with monthly interest payments and a 30-month tenure. Additionally, the Board approved calling the 75% balance amount from warrant holders for conversion into equity shares.

• · Debenture Trustee appointed: Catalyst Trusteeship Limited
• · Merchant Banker appointed: Horizon Management Private Limited
• · Tenure of NCDs: 30 months from date of allotment
• · Coupon/interest payment schedule: Monthly
• · Principal repayment: 30% at 18th month, 30% at 24th month, 40% at 30th month
• · Delay penalty: 3% per annum over coupon rate on default amounts for over 3 months
• · Security cover ratio: 1.35x with at least 135% of security cover from secured receivables
• · Board meeting timing: commenced 3:00 PM, concluded 4:00 PM on June 4, 2026
• · The convertible warrants were originally allotted on December 28, 2024; 25% was paid upfront, 75% was now called

04-06-2026

U.P. Hotels Ltd. has informed BSE about the newspaper publication of its postal ballot notice regarding voluntary delisting, published in Financial Express and Jansatta on June 4, 2026. The filing itself is a procedural update, but the underlying action—voluntary delisting—is a significant corporate event. No financial performance data is included in this filing.

• · The postal ballot notice and explanatory statement are available on the company's website at www.hotelclarks.com.
• · The newspaper publication date is June 4, 2026.
• · The filing references a prior letter dated June 2, 2026, regarding the postal ballot notice.

04-06-2026

Smart Services Private Limited has issued a corrigendum to the detailed public statement for its open offer to acquire up to 64,86,000 equity shares (25% of voting capital) of Sharp India Limited at ₹10 per share. The corrigendum updates the offer schedule, notably shifting the opening date from June 8 to June 16, 2026, and the closing date from June 19 to June 30, 2026. Additionally, the acquirer has already acquired 1,94,58,000 equity shares on June 2, 2026, pursuant to a share purchase agreement.

• · The corrigendum was issued following SEBI Observation Letter no. HO/49/12/11(54)2026-CFD-RAC-DCR2/I/12668/2026 dated May 29, 2026.
• · The identified date for determining shareholders eligible to receive the letter of offer was revised from May 22, 2026 to June 2, 2026.
• · The last date for revising the offer price is now June 12, 2026 (previously June 4, 2026).
• · The post-offer advertisement is scheduled for July 7, 2026 (previously June 29, 2026).
• · Payment of consideration for acquired shares is now due by July 14, 2026 (previously July 6, 2026).

04-06-2026

Pyxus International reported a slight decline in total sales and other operating revenues for FY2026, down 2.8% to $2,413.0M from $2,481.3M in FY2025, driven by a 4.3% drop in leaf product revenues and a 0.4% decrease in kilos sold. However, gross profit improved 1.4% to $347.7M and gross margin expanded to 14.4% from 13.8%, while operating income grew 6.1% to $162.7M. Net income attributable to Pyxus fell 3.9% to $14.6M, and the company generated negative operating cash flow of $208.5M, though it ended the year with $137.7M in cash (up 61.1%) and increased total borrowing capacity to $1,214.4M.

• · Gross profit margin improved to 14.4% in FY2026 from 13.8% in FY2025.
• · Processing and other gross profit margin rose to 20.1% from 17.7%.
• · All Other segment swung from a gross loss of $2.2M in FY2025 to a gross profit of $1.7M in FY2026.
• · Interest expense increased 5.0% to $134.4M.
• · Income tax expense rose 20.7% to $30.3M.
• · Income from unconsolidated affiliates more than doubled to $17.4M.
• · Net cash used in operating activities worsened to $208.5M from $13.4M, driven by a large increase in trade receivables ($254.9M) and inventories ($60.4M).
• · Investing activities provided $191.4M, primarily from collections of securitized trade receivables ($200.7M).
• · Financing activities provided $72.5M, mainly from net short-term borrowings of $77.3M.
• · Total contractual obligations amount to $2,041.0M, with $1,472.7M due in FY2027.
• · Current ratio declined to 1.4:1 from 1.5:1.
• · Working capital increased 3.5% to $397.7M.
• · The company had no gain on debt retirement in FY2026 versus $8.2M in FY2025.
• · Restructuring and asset impairment charges increased 26.1% to $2.9M.
• · Other expense, net increased 17.1% to $19.2M.

04-06-2026

Jagsonpal Pharmaceuticals Limited has allotted 2,96,320 equity shares of ₹2 each to eligible employees under the JPL ESOP 2022 upon exercise of vested options. The allotment increases the company's paid-up share capital from ₹13,10,78,300 (6,55,39,150 shares) to ₹13,16,70,940 (6,58,35,470 shares). The shares rank pari-passu with existing shares and were issued at exercise prices ranging from ₹94.00 to ₹115.60 per share.

• · The shares were issued in three tranches: 2,28,000 shares at ₹94.00, 59,920 shares at ₹113.60, and 8,400 shares at ₹115.60.
• · The premium per share ranges from ₹92.00 to ₹113.60.
• · The distinctive numbers of the shares are 6,71,39,151 to 6,74,35,470.
• · ISIN of the shares is INE048B01035.
• · No lock-in period applies to the allotted shares.

04-06-2026

Syndax Pharmaceuticals announced a private placement of $250.0 million in 2.25% Convertible Senior Notes due 2031, expected to close on June 10, 2026, with net proceeds of approximately $243 million for general corporate purposes. The notes carry a 2.25% interest rate, mature on June 15, 2031, and have an initial conversion price of $24.76 per share, representing a 35% premium over the stock's last reported sale price on June 3, 2026. The company is a commercial-stage biopharmaceutical firm with FDA-approved products Revuforj and Niktimvo, but the filing does not disclose any negative or flat performance metrics.

• · Notes are senior unsecured obligations with interest payable semiannually on June 15 and December 15, starting December 15, 2026.
• · Noteholders may convert at any time prior to March 15, 2031 only upon certain circumstances; after that date, conversion is allowed at any time until the second scheduled trading day before maturity.
• · Upon conversion, Syndax may pay cash, shares of common stock, or a combination, at its election.
• · Syndax cannot redeem the notes before June 20, 2029; after that, redemption is allowed if stock price is at least 130% of conversion price for 20 trading days in a 30-day period.
• · In a fundamental change, noteholders can require Syndax to repurchase notes at 100% of principal plus accrued interest.
• · The notes and any conversion shares are not registered under the Securities Act and cannot be offered or sold in the U.S. without registration or an exemption.

04-06-2026

Eicher Motors received a demand order from the Principal Commissioner of Customs, Kolkata, for Rs. 1.64 Crore (including duty of Rs. 0.82 Crore and penalty of Rs. 0.82 Crore) related to preferential tariff exemption claimed on imports in 2020. The company considers the demand not maintainable and plans to appeal, with no expected material financial impact.

• · Order received via email on June 3, 2026, from Principal Commissioner of Customs (Preventive), Kolkata.
• · Demand relates to one shipment during 2020 for preferential tariff exemption.
• · Company is evaluating options including filing an appeal and does not envisage any relevant impact on financials, operations, or other activities.

04-06-2026

CONMED Corporation entered into privately negotiated purchase agreements on June 3, 2026 to repurchase approximately $645.2 million aggregate principal amount of its 2.25% Convertible Senior Notes due 2027 for approximately $637.2 million in cash. The transaction is expected to close on June 15, 2026, subject to customary closing conditions. This debt repurchase reduces the company's outstanding convertible debt but also consumes significant cash reserves.

• · The repurchase price of $637.2M represents a discount of approximately $8.0M (1.24%) from the principal amount of $645.2M.
• · The Notes carry a 2.25% coupon and mature in 2027.
• · The purchase agreements were entered into on June 3, 2026, and the filing was made on June 4, 2026.

04-06-2026

BeyondSpring Inc. announced a leadership transition effective July 1, 2026, designed to sharpen execution on its confirmatory Phase 3 DUBLIN-4 trial for Plinabulin in NSCLC. Founder Dr. Lan Huang will remain Chairman but cede the CEO role to Min Qiu, while Dr. Jen Majeti becomes Vice Chairman and Na Li becomes CFO. The restructuring aims to give each of BeyondSpring and SEED Therapeutics (where Dr. Huang is CEO) a fully dedicated executive leader. However, the departure of the founder from day-to-day operations introduces key-person transition risk, and no financial guidance or enrollment timelines were disclosed, creating uncertainty on execution pace and capital needs.

• · IP portfolio for Plinabulin includes composition-of-matter protection extending through 2036 with potential Hatch-Waxman extension to 2041.
• · Incoming CEO Min Qiu previously led an RMB 1.3 billion licensing collaboration at Hengrui Pharma and is fluent in Chinese, English, and Japanese.
• · New CFO Na Li holds Shanghai Stock Exchange Board Secretary qualification and has board secretary experience for Main Board and Third Board-listed companies.
• · BeyondSpring retains a meaningful equity stake in SEED Therapeutics.
• · SEED Therapeutics has advanced its lead RBM39 degrader (ST-01156) into Phase 1 development with cornerstone investors Eli Lilly and Eisai.
• · DUBLIN-3 results published in The Lancet Respiratory Medicine (2024).

04-06-2026

Advanced Biomed Inc. (ADVB) filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held on June 30, 2026. The Board recommends voting FOR the election of five director nominees, FOR the advisory vote on executive compensation, ONE YEAR for the frequency of future advisory votes, FOR the ratification of WWC, P.C. as independent auditor, and FOR adjournment if needed. As of the record date (May 29, 2026), there were 1,652,133 shares of common stock outstanding and entitled to vote.

• · The Annual Meeting will be held in person at No. 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan on June 30, 2026 at 10:00 a.m. Eastern Time.
• · A quorum requires a majority of outstanding shares present in person or by proxy.
• · Directors are elected by a plurality of votes cast; broker non-votes have no effect on Proposal 1.
• · Proposal 2 (advisory vote on executive compensation) requires a majority of votes cast for approval.
• · Proposal 3 (frequency) will be decided by the option receiving the most votes among one, two, or three years.
• · Proposal 4 (ratification of auditor) and Proposal 5 (adjournment) require a majority of votes cast in favor.
• · Broker non-votes will be counted for quorum but not for non-routine proposals (Proposals 1, 2, 3, 5).
• · Proxies may be revoked by submitting a later-dated proxy, written revocation, or voting in person.
• · Final voting results will be filed on Form 8-K within four business days after the meeting.
• · Xiaomin Chen has over 20 years of experience in AI and fintech, previously worked at Google Inc.
• · Mingze Yin has over 11 years of financial and investment banking experience.
• · Jing Zhang has more than 25 years of financial management experience.
• · Cheang I Kei has experience in corporate governance and legal management.
• · Mingyue Cai is also an independent director nominee.

04-06-2026

Syschem (India) Ltd. has amicably resolved a dispute with M/S Lotus Builders through a Settlement Agreement dated June 4, 2026. The matter was previously pending before the NCLT, Chandigarh, concerning dishonoured cheques issued by Syschem. The company will pay a settlement amount of ₹1,25,00,000 (One Crore Twenty-Five Lakhs) as full and final settlement, with no material adverse impact on financials or operations beyond the settlement payment.

• · The original disclosure was made on February 26, 2024, under Regulation 30 of SEBI LODR Regulations.
• · The dispute involved dishonour of certain cheques issued by Syschem to Lotus Builders for payment obligations.
• · Post settlement, the parties will file applications for withdrawal/disposal of proceedings before NCLT.
• · The company stated no material adverse impact on financials, operations, or other activities except for the settlement payment.

04-06-2026

IVP Limited has disclosed that Mr. Ravi Ranjan Jha, the employee accused of fraud, has filed a civil suit against the company and certain officials in a court in Gautam Budh Nagar, Greater Noida. The company believes the claims are not tenable and will defend its interests through legal action. This update follows several prior intimations regarding the fraud, but no financial figures or quantitative impacts have been disclosed.

• · The civil suit was filed by the accused employee, Mr. Ravi Ranjan Jha, against IVP Limited and certain of its officials.
• · The suit is filed in a court in Gautam Budh Nagar, Greater Noida, Uttar Pradesh.
• · The company states the claims are not tenable and will take necessary legal actions to defend its interests.
• · This is an update to prior intimations dated January 13, 2026, January 22, 2026, January 29, 2026, May 21, 2026, and June 01, 2026.

04-06-2026

Lyka Labs Limited received a favorable order from the National Company Law Appellate Tribunal (NCLAT), New Delhi, on June 4, 2026, directing Modi Life Care Industries Limited to pay a claim amount of ₹63,00,000 (Rupees Sixty Three Lacs) within 30 days. The company stated that apart from this receipt, there is no material impact on its financials, operations, or other activities.

• · The order was passed in Company Appeal (AT) INS.NO. 726 of 2024 filed under Section 61 of the Insolvency and Bankruptcy Code 2016.
• · The payment must be made within 30 days from the date of the order (June 4, 2026).
• · The company explicitly stated there is no material impact on financials, operations, or other activities except for the received amount.

04-06-2026

Hitech Corporation Limited has informed the stock exchanges that its Board of Directors will meet on June 9, 2026, to consider a voluntary delisting proposal initiated by the promoter group (led by Geetanjali Trading and Investments Private Limited). The acquirers have offered an indicative price of INR 353 per share, representing a 40.08% premium over the floor price of INR 252. The board will review due diligence reports, the floor price certificate, and other regulatory requirements before deciding on the delisting proposal.

• · The board meeting is scheduled for June 9, 2026.
• · The trading window will be closed until 48 hours after the board meeting outcome is announced.
• · The due diligence report was prepared by a peer-reviewed company secretary as per Regulation 10(2) and 10(3) of SEBI Delisting Regulations.
• · The floor price certificate was received by the company on May 28, 2026.
• · The initial public announcement regarding the delisting was made on May 25, 2026.

04-06-2026

Novartis India Limited has received the final Letter of Offer from Axis Capital Limited, the Manager to the Open Offer, for the acquisition of up to 64,19,608 equity shares (26% of voting share capital) by WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners (the Acquirers), along with persons acting in concert, at a price of INR 860.64 per share. The offer is made under SEBI (SAST) Regulations and is not conditional upon any minimum acceptance level. The Letter of Offer has been dispatched to public shareholders as of the identified date of May 27, 2026, and the tendering period is expected to open on June 10, 2026.

• · The open offer is not conditional upon any minimum level of acceptance.
• · No competing offer has been made as of the date of the Letter of Offer.
• · The Acquirers and PACs may withdraw the offer in accordance with specified terms; if withdrawn, a public announcement must be made within 2 working days.
• · The Offer Price and Offer Size may be revised upward at any time prior to the last working day before the tendering period commences.
• · Non-resident shareholders (NRIs, OCBs, FPIs) must submit required approvals (e.g., RBI) to tender shares; otherwise, their shares may be rejected.
• · The identified date for determining public shareholders is May 27, 2026.
• · The Letter of Offer was dispatched to shareholders on June 4, 2026.
• · The committee of independent directors is required to give its recommendation by June 9, 2026.
• · The last date for upward revision of the Offer Price and/or Offer Size is June 9, 2026.
• · The tendering period is expected to open on June 10, 2026.

04-06-2026

ONGC has informed the stock exchanges that the transcript of the conference call with analysts and investors held on May 27, 2026 has been uploaded on the company's website. This is a routine disclosure under SEBI regulations and does not contain any financial results or material updates.

• · Transcript of the conference call held on May 27, 2026 has been uploaded on the company's website.
• · The communication is dated June 04, 2026 and references prior intimation dated May 22, 2026 and May 27, 2026.

04-06-2026

Paytm approved providing Default Loss Guarantee (DLG) of up to ₹90 crore each to lending partners Muthoot Fincorp and Kisetsu Saison Finance under its existing loan distribution model. Separately, Independent Director Ashit Ranjit Lilani withdrew his consent for reappointment for a second term due to other professional commitments, and his current term will end on July 4, 2026. The DLG arrangement supports Paytm's loan distribution business but introduces financial guarantee expenses of up to ₹90 crore per partner over time.

• · DLG will be provided in the form of Fixed Deposits or Bank Guarantee.
• · The DLG is net of invocations and applies to loans disbursed from time to time.
• · Mr. Lilani's current term ends on July 4, 2026, and he will also cease as chairperson of the Nomination and Remuneration Committee and Stakeholders’ Relationship Committee, and as a member of the Audit Committee and Investment Committee.
• · The Board noted Mr. Lilani's withdrawal and placed on record its appreciation for his services.
• · Paytm is a professionally managed company with no identified promoter or promoter group.

04-06-2026

Ashok Leyland reported record FY26 results with all-time high CV volume (220,437 units), revenue (₹44,007 Cr, +13.6% YoY), EBITDA (₹2,066 Cr in Q4, margin 14.6%), and net cash (₹5,899 Cr). Q4 revenue grew 19% YoY to ₹14,161 Cr and PAT (excl. exceptional items) rose 13% YoY to ₹1,405 Cr. However, material cost as a percentage of revenue increased 80 bps YoY in Q4 to 71.4%, and export volumes in Q4 were marginally lower YoY due to logistics issues. The company remains cautiously optimistic about FY27 demand but flags macroeconomic headwinds including diesel price increases and commodity volatility.

• · Domestic MHCV trucks volume FY26: 105,905 units with 30.2% market share; MHCV bus volume: 20,840 units with 34.1% market share.
• · LCV VAHAN market share for Q4 FY26 was 12.8% (gain of 90 bps YoY); full year LCV VAHAN market share 12.7% (gain of 80 bps YoY).
• · Export volumes in Q4 were marginally lower YoY at 5,322 units due to international logistics issues in March.
• · Switch India achieved net profitability in FY26 and market leadership in electric buses and 2-4 ton electric LCVs.
• · OHM Mobility operational fleet improved to over 1,400 e-buses.
• · HLF AUM expanded 24% YoY to ~₹59,000 Cr; HHF AUM grew 15% YoY to ~₹16,000 Cr.
• · Consolidated net NPAs of HLF and HHF at approximately 1.4%.
• · Reverse merger of HLF with NBL Ventures expected to consummate within this or next quarter.
• · Board recommended a second interim dividend of ₹2.50 per share.
• · Capex for FY26 was ₹1,050 Cr, primarily towards new products, alternate powertrain technologies, and EVs.
• · Investments in subsidiaries in Q4 was ₹371 Cr, primarily towards repayment of loans in off-tier books.
• · Material cost as a percentage of revenue for Q4 was 71.4%, higher by 80 bps YoY; for full year 71.4%, 10 bps higher than last year.
• · Price increase of about 1% effective January was recovered for the entire quarter.
• · Management expects Q1 FY27 export volumes may drop due to logistics issues, but normalizing.
• · RAK factory production had to be dropped due to local challenges; aiming to return to 100% capacity utilization in a few weeks.
• · Dow Jones Sustainability Index ESG score improved to global top 2% in industrial engineering and electrical equipment companies.
• · RE100 achievement: 77% overall (vs 69% in FY25), Tamil Nadu plants at 91%.

04-06-2026

Kopran Limited held meetings of equity shareholders, secured creditors, and unsecured creditors on June 3, 2026, pursuant to NCLT Mumbai Bench order dated April 9, 2026, to consider and approve the Scheme of Amalgamation between Kopran Laboratories Limited (Transferor) and Kopran Limited (Transferee). The resolution was passed with the requisite majority across all three classes. The voting results show 99.9551% of equity shareholders voted in favor, with only 0.0449% against, indicating strong support for the scheme.

• · The meetings were convened pursuant to NCLT Mumbai Bench order dated April 9, 2026 in Company Scheme Application No. CA(CAA)/48(MB)/2026.
• · The e-voting period for equity shareholders was from May 27, 2026 (09:00) to June 2, 2026 (17:00).
• · The meeting was held through Video Conferencing/Other Audio Visual Means as per MCA Circulars.
• · The resolution was a Special Resolution.
• · The scrutinizer's report was submitted in Form MGT-13.
• · The meeting ended at 10:48 AM on June 3, 2026.

04-06-2026

Minerva Neurosciences, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation on June 4, 2026. The amendment limits the monetary liability of directors and officers for breach of fiduciary duty to the fullest extent permitted under Delaware law, and reserves Article NINTH. The amendment was approved by the Board and stockholders.

• · The original certificate of incorporation was filed on April 23, 2007 under the name Cyrenaic Pharmaceuticals, Inc.
• · The amendment to Article EIGHTH limits director and officer liability for monetary damages for breach of fiduciary duty, with 'officer' defined per Section 102(b)(7) of the DGCL.
• · Article NINTH is now reserved.
• · The amendment was adopted in accordance with Section 242 of the DGCL.

04-06-2026

Kura Oncology, Inc. filed an 8-K on June 4, 2026, reporting that stockholders approved an amendment to the Amended and Restated 2014 Equity Incentive Plan, increasing the share reserve by 6,500,000 shares to a total of 41,077,686 shares. The filing also covers standard administrative provisions for equity awards, including options, restricted stock, and performance awards, with no specific financial results or officer changes detailed.

• · The plan was originally adopted in 2015 and has been amended multiple times, with the latest stockholder approval on June 4, 2026.
• · The share reserve includes shares from prior annual increases and stockholder approvals from 2023 (4,050,000), 2024 (5,500,000), and 2025 (4,750,000).
• · Full Value Awards reduce the share reserve by 1.44 shares per share issued, while options/SARs with exercise price at least 100% of fair market value reduce it by 1 share per share.
• · The plan allows for delegation of administration to a committee and permits grants to employees, directors, and consultants.

04-06-2026

Highwoods Realty Limited Partnership and Highwoods Properties, Inc. entered into a Sixth Amendment to their Sixth Amended and Restated Credit Agreement on June 3, 2026, with Bank of America as Administrative Agent. The amendment modifies certain provisions, reallocates Term A-2 Loans among lenders, and requires compliance with financial covenants as of March 31, 2026, while confirming no Default exists and no Material Adverse Effect has occurred since December 31, 2025.

• · The amendment reallocates Outstanding Term A-2 Loans among Term A-2 Lenders to reflect each lender's Applicable Percentage.
• · Conditions precedent include delivery of legal opinions from Poyner Spruill LLP, Jeffrey D. Miller, and Haynes and Boone, LLP.
• · The Borrowers certified compliance with financial covenants as of March 31, 2026, and that no Material Adverse Effect has occurred since December 31, 2025.
• · The amendment requires delivery of Beneficial Ownership Certification for any Loan Party qualifying as a 'legal entity customer' under the Beneficial Ownership Regulation.
• · The Credit Agreement is governed by New York law.